Prostate cancer recurrence after surgery is nearly double in smokers
the ONA take:
New research points out another cancer prognosis worsened by smoking. This research from an international group of scientists and clinicians from the United States and Europe found that current smokers and those who quit less than 10 years previously are at higher risk of prostate cancer recurrence after surgery.
The group retrospectively reviewed biochemical prostate cancer recurrence in 7,191 men who had undergone radical prostatectomy.
Among the men, approximately one-third each were never smokers, former smokers, and current smokers. After a median follow-up of 28 months, current smokers had approximately double the chance of the cancer recurring. Those who had quit within the last 10 years had a significantly higher risk.
The researchers report that their results confirm what is seen in many other cancers: smoking increases the risk of recurrence after initial treatment.
Furthermore, they recommend that patients stop smoking after a diagnosis of prostate cancer is determined.
Current smokers and those who quit less than 10 years previously are at higher risk of prostate cancer recurrence after surgery.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|